Search research articles
Contact Us
Filters
Showing results (101-110 of 130) with videos related to
Page
of 13
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 17, 2020
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)
Yasir Alayed, Harvey Quon, Aldrich Ong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 20, 2018
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial
Harvey C Quon, Aldrich Ong, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 13, 2022
Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
Rohann J M Correa, Gerard Morton, Hans T Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 9, 2017
Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer
Samantha C Sodergren, Colin D Johnson, Alexandra Gilbert, et al.
The Journal of Urology
|
February 12, 2019
Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK
Rohann J M Correa, Alexander V Louie, Michael Staehler, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 21, 2020
Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK)
Shankar Siva, Rohann J M Correa, Andrew Warner, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer
Wee Loon Ong, Patrick Cheung, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer
Wee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 8, 2023
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial
Wee Loon Ong, Patrick Cheung, Hans Chung, et al.
European Urology Focus
|
June 29, 2019
The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Rohann J M Correa, Alexander V Louie, Nicholas G Zaorsky, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 130) with videos related to
Sort By:
Page
of 13
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 17, 2020
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)
Yasir Alayed, Harvey Quon, Aldrich Ong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 20, 2018
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial
Harvey C Quon, Aldrich Ong, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 13, 2022
Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
Rohann J M Correa, Gerard Morton, Hans T Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 9, 2017
Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer
Samantha C Sodergren, Colin D Johnson, Alexandra Gilbert, et al.
The Journal of Urology
|
February 12, 2019
Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK
Rohann J M Correa, Alexander V Louie, Michael Staehler, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 21, 2020
Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK)
Shankar Siva, Rohann J M Correa, Andrew Warner, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer
Wee Loon Ong, Patrick Cheung, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer
Wee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 8, 2023
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial
Wee Loon Ong, Patrick Cheung, Hans Chung, et al.
European Urology Focus
|
June 29, 2019
The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Rohann J M Correa, Alexander V Louie, Nicholas G Zaorsky, et al.
Page
of 13